Immunoadsorption for connective tissue disease.
Distinct connective tissue diseases (CTD's) such as systemic lupus erythematosus (SLE), systemic sclerosis, mixed connective tissue disease as well as dermato- and polymyositis comprise a group of diseases, where autoantibodies are not merely indicators of autoimmune disease, but also play an relevant role in the underlying pathogenicity. This knowledge led to the development of antibody targeting therapies using rituximab or belimumab. Upon this, therapeutic plasma exchange, and more recently immunoadsorption (IAS) have been successfully applied to remove pathogenic autoantibodies under various conditions in some of these CTD's. While the technique of IAS is superior to plasma exchange in regard to specificity and efficacy, the clinical use of IAS in CTD's is currently restricted to a small proportion of clinical situations with either refractory disease or the necessity to avoid aggressive immunosuppressive regimens. Despite the presence of a large number of case series and few controlled trials using IAS, there is a need for further prospective randomized trials to clearly define the role of IAS in these CTD's.
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Fetscherstr 74, 01307 Dresden, Germany. bernd.hohenstein@uniklinikum-dresden.de
B
B
Hohenstein
S R
SR
Bornstein
M
M
Aringer
D000042:Absorption; D001323:Autoantibodies / Q000097:blood*; D015551:Autoimmunity; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000009:adverse effects / Q000379:methods*; D003240:Connective Tissue Diseases / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007163:Immunosorbent Techniques / Q000009:adverse effects; D007164:Immunosorbents / Q000009:adverse effects / Q000627:therapeutic use*; D010951:Plasma Exchange; D016896:Treatment Outcome
D001323:Autoantibodies; D015415:Biomarkers; D007164:Immunosorbents